Spark Breaks Ground on Gene Therapy Innovation Center on Drexel Campus in Philadelphia

Sixteen months since the original announcement, Spark Therapeutics broke ground this week on its Gene Therapy Innovation Center in University City on the Drexel University Campus in Philadelphia. Spark, now a Roche company, developed the first FDA-approved gene therapy, Luxturna. The FDA approved the drug in 2017 to treat patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy.